Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
NCT ID: NCT05697575
Last Updated: 2023-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
336 participants
OBSERVATIONAL
2023-02-01
2024-05-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)
NCT06707987
Cytoflavin in Combination With Reperfusion in Stroke Patients
NCT05297851
Stroke Treatment With Acute Reperfusion and Simvastatin
NCT01073007
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
NCT01955707
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
NCT03151993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;
* Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.
Exclusion Criteria
* The presence of a contraindication to thrombolytic therapy of ischemic stroke;
* Pregnancy or lactation.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Society for Neurosonology and Cerebral Circulation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Igor A Voznjuk, Prof
Role: STUDY_DIRECTOR
First St. Petersburg State Medical University named after I.P. Pavlov
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ekaterina Gogoleva
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REPIN-Forte
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.